Article thumbnail

Noninvasive brain imaging for experimental medicine in drug discovery

By Paul M. Matthews and Richard Geoffrey Wise


There is a widely shared perception that it is becoming increasingly urgent to find reliable measures related to therapeutic efficacy for use as early as possible in drug development. The inadequate understanding of diseases, limitations of animal models and difficulties in using their responses to anticipate drug effects in humans highlights the need to develop tools in experimental medicine to characterise human disease directly. Noninvasive imaging, particularly positron emission tomography and magnetic resonance imaging, provide a powerful range of methods for serial observation of drug distribution and interactions, and for assessing potential therapeutic mechanisms. Using imaging technology to establish biological proof-of-principle and as a pharmacodynamic marker for dose ranging would contribute greatly to the speed and efficiency of early decision making in new drug development. Imaging methods offer the ultimate promise for the development of clinically predictive surrogate markers of disease responses to new drugs

Topics: BF Psychology, RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry, RM Therapeutics. Pharmacology
Publisher: Informa Healthcare
Year: 2006
DOI identifier: 10.1517/17460441.1.2.111
OAI identifier: oai:
Provided by: ORCA
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.